Pfizer News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

30.07.24	Pfizer Inc. Q2 Profit Decreases, But Beats Estimates (RTTNews)
30.07.24	Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance (Businesswire)
25.07.24	Pfizer Gets EC's Conditional Authorization For Durveqtix Genetherapy In Hemophilia B (RTTNews)
25.07.24	European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B (Businesswire)
24.07.24	Pfizer's Phase 3 AFFINE Study Of Hemophilia A Gene Therapy Candidate Meets Primary Goal (RTTNews)
24.07.24	Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate (Businesswire)
11.07.24	Pfizer Advances Once-Daily Formulation Of Oral GLP-1 Receptor Agonist Danuglipron (RTTNews)
11.07.24	Pfizer Advances Development of Once-Daily Formulation of Oral GLP-1 Receptor Agonist Danuglipron (Businesswire)
09.07.24	Pfizer Chief Scientific Officer Mikael Dolsten To Step Down (RTTNews)
09.07.24	Pfizer to Launch Process to Identify a Successor for Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development (Businesswire)
03.07.24	GSK Acquires Global Rights For MRNA Vaccines For Influenza & COVID-19 In CureVac Deal - Quick Facts (RTTNews)
01.07.24	Cyrus Taraporevala Elected to Pfizer’s Board of Directors (Businesswire)
27.06.24	Pfizer, BioNTech Get CHMP's Positive Opinion For Marketing Authorization Of Omicron JN.1 Vaccine (RTTNews)
27.06.24	Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union (Businesswire)
26.06.24	Pfizer Declares Third-Quarter 2024 Dividend (Businesswire)
18.06.24	Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts (Businesswire)
14.06.24	ELREXFIO™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma (Businesswire)
13.06.24	Pfizer's Phase 3 Duchenne Gene Therapy Trial Fails To Meet Primary And Secondary Endpoints (RTTNews)
12.06.24	Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with Duchenne Muscular Dystrophy (Businesswire)
03.06.24	Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference (Businesswire)
01.06.24	Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/?Refractory Diffuse Large B-cell Lymphoma (DLBCL) (Businesswire)
31.05.24	Pfizer's Phase 3 Crown Trial Of Lobrena Reports 5-year Non-progression Results In NSCLC Patients (RTTNews)
31.05.24	Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression (Businesswire)
23.05.24	Pfizer's Hospira Recalls Select Hydrochloride Injection Carpuject Units (RTTNews)
16.05.24	Arvinas, Pfizer, Report 6-month Follow Up Data From Phase 1b Study Of Vepdegestrant+Palbociclib (RTTNews)
13.05.24	Amazon, Microsoft, Pfizer To Invest Billions In French Projects (RTTNews)
06.05.24	Andrew Baum To Oversee Pfizer's Innovation, Portfolio Strategy (RTTNews)
06.05.24	Pfizer Announces New Chief Strategy and Innovation Officer (Businesswire)
01.05.24	Pfizer Boost FY24 Adj. EPS Outlook - Update (RTTNews)
01.05.24	Pfizer Inc. Q1 Profit Decreases, but beats estimates (RTTNews)
01.05.24	Pfizer Reports First-Quarter 2024 Results (Businesswire)
30.04.24	Biotech Stocks Facing FDA Decision In May 2024 (RTTNews)
30.04.24	Pfizer,Genmab: FDA Grants Full Approval For TIVDAK To Treat Recurrent Or Metastatic Cervical Cancer (RTTNews)
30.04.24	FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer (Businesswire)
29.04.24	Labcorp: FDA Approves NAbCyte Companion Diagnostic - Quick Facts (RTTNews)
29.04.24	Pfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual Meeting (Businesswire)
26.04.24	Pfizer's Beqvez Receives FDA Approval For Treatment Of Adults With Hemophilia B (RTTNews)
26.04.24	U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B (Businesswire)
24.04.24	Pfizer Declares Second-Quarter 2024 Dividend (Businesswire)
22.04.24	Pfizer's Emblaveo Gets EU Marketing Authorization For Serious Infectious Disease (RTTNews)
22.04.24	European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options (Businesswire)
11.04.24	Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25 (Businesswire)
09.04.24	Pfizer Reports Positive Results From Phase 3 Abrysvo Vaccine Study (RTTNews)
09.04.24	Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease (Businesswire)
20.03.24	Pfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with Analysts (Businesswire)
19.03.24	Haleon Announces Pricing And Upsize Of Secondary Offering By Pfizer At $7.85/ADS (RTTNews)
18.03.24	Pfizer Plans To Sell About 630 Mln Haleon Shares (RTTNews)
13.03.24	Pfizer's PREVENAR 20 Pneumococcal Conjugate Vaccine For Infants And Children Gets EU Approval (RTTNews)
13.03.24	European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease (Businesswire)
12.03.24	Pfizer: ADCETRIS Phase 3 Trial In Blood Cancer Shows Positive Overall Survival (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.11.24		Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone
22.11.24		Freundlicher Handel in New York: Dow Jones präsentiert sich am Freitagnachmittag fester
22.11.24		Börse New York in Grün: Dow Jones bewegt sich am Mittag im Plus
22.11.24		Zuversicht in London: FTSE 100 beendet die Freitagssitzung in der Gewinnzone
22.11.24		Gute Stimmung in Europa: Anleger lassen STOXX 50 letztendlich steigen
22.11.24		Handel in Frankfurt: TecDAX letztendlich in Grün
22.11.24		Freundlicher Handel: Börsianer lassen SPI schlussendlich steigen

22.11.24

Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone

22.11.24

Freundlicher Handel in New York: Dow Jones präsentiert sich am Freitagnachmittag fester

22.11.24

Börse New York in Grün: Dow Jones bewegt sich am Mittag im Plus

22.11.24

Zuversicht in London: FTSE 100 beendet die Freitagssitzung in der Gewinnzone

22.11.24

Gute Stimmung in Europa: Anleger lassen STOXX 50 letztendlich steigen

22.11.24

Handel in Frankfurt: TecDAX letztendlich in Grün